# AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis

> **NCT02082262** · PHASE3 · COMPLETED · sponsor: **Allergan** · enrollment: 140 (actual)

## Conditions studied

- Conjunctivitis, Allergic

## Interventions

- **DRUG:** AGN-229666

## Key facts

- **NCT ID:** NCT02082262
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2016-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02082262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02082262, "AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02082262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*